Liminal BioSciences

Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using drug discovery platform and a data driven approach. The firm has business operations in Canada and the United Kingdom. Its small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose clinical trial and anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support development plan. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Liminal BioSciences is a biopharmaceutical corporation supplying state-of-the-art technologies for bio-separations as well as therapeutic products. It specializes in discovering, developing, and commercializing novel small molecule compounds for respiratory, liver, and renal diseases. The company focuses specifically on developing solutions for rare and orphan diseases. Liminal BioSciences was founded in 1992 and is headquartered in Laval, Quebec.

LAVAL, QC, and CAMBRIDGE, England, Dec. 15, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the first subject has been dosed in the Company's fezagepras Phase 1 multiple...

Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q3 2020 Results - Earnings Call Transcript

LAVAL, QC and CAMBRIDGE, England, Nov. 13, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to...

Liminal Biosciences to Present at The Stifel Virtual Healthcare Conference

LAVAL, QC and CAMBRIDGE, England, Nov. 10, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it will now report its financial results for the third quarter ended September...

Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call

PDUFA date extended by FDA from March 5, 2021 to June 5, 2021 Earnings call moved forward to Wednesday November 11th LAVAL, QC, and CAMBRIDGE, England, Nov. 8, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage...

Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(plasminogen) BLA

LAVAL, QC and CAMBRIDGE, England, Nov. 6, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it will report its financial results for the third quarter ended September 30th...

Liminal Biosciences To Report Q3 2020 Results And Hold Conference Call

LAVAL, QC and CAMBRIDGE, England, Nov. 5, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced the acceptance of two abstracts related to the Company's clinical development...

Liminal BioSciences Announces Upcoming Presentations for Ryplazim® (plasminogen) at the 62nd ASH Annual Meeting and Exposition

- FDA assigns PDUFA target action date of March 5, 2021 LAVAL, QC and CAMBRIDGE, England, Sept. 21, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug...

Liminal BioSciences Provides Update on Progress on BLA for Ryplazim®(plasminogen)

ADMA Biologics

AstraZeneca

BioNTech SE

Cerus

Pfizer

Sonnet BioTherapeutics

The pandemic highlights how far medical science has come. It also highlights how exciting the future is.

Biotech Boom: The Race for COVID-19 Vaccines

Grifols, S.A.

Kamada

ThermoGenesis Holdings, Inc

T2 Biosystems

Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use of investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients.

These Plasma Stocks Are Surging After FDA's Convalescent EUA

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients as part of the agency’s ongoing efforts to fight COVID-19.

FDA Issues Emergency Use Of Convalescent Plasma For COVID–19 Treatment

Liminal BioSciences: Under New Management And Chasing Ryplazim Approval

LAVAL, QC, and CAMBRIDGE, England, Aug. 6, 2020 /PRNewswire/ - Liminal BioSciences Inc.

Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference

Chanticleer Hlds

Plasma stocks were trading higher Friday after President Donald Trump encouraged Americans who have recovered from COVID-19 to donate their convalescent blood plasma as a treatment for the virus.

Plasma Stocks Move After Trump Roundtable On COVID-19

LAVAL, QC and CAMBRIDGE, England, July 2, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc.,...

Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy

LAVAL, QC and CAMBRIDGE, England, June 30, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences, has...

Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors

LAVAL, QC and CAMBRIDGE, England, June 30, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today provided a guidance update on the timing of certain expected key milestones for...

Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020

LAVAL, QC and CAMBRIDGE, United Kingdom, June 11, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today announced that Kenneth Galbraith, Chief Executive Officer at Liminal...

Liminal BioSciences to Present at Raymond James Human Health Innovation Conference

LAVAL, QC, and CAMBRIDGE, United Kingdom, May 28, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today announced that Kenneth Galbraith, Chief Executive Officer at Liminal...

News for Liminal BioSciences Stock (LMNL)